Shandong Boyuan Pharmaceutical & Chemical Co., Ltd. (SHE:301617)
73.64
+0.19 (0.26%)
At close: Feb 13, 2026
SHE:301617 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 1,392 | 1,326 | 1,021 | 796.66 | 523.69 | 378.93 |
Other Revenue | 2.01 | 2.01 | 3.68 | 1.82 | 0.68 | 0.52 |
| 1,394 | 1,328 | 1,025 | 798.47 | 524.37 | 379.44 | |
Revenue Growth (YoY) | 8.45% | 29.53% | 28.39% | 52.27% | 38.20% | 12.16% |
Cost of Revenue | 1,095 | 999.05 | 739.4 | 520.8 | 347.04 | 265.33 |
Gross Profit | 299.78 | 328.83 | 285.75 | 277.67 | 177.33 | 114.12 |
Selling, General & Admin | 47.23 | 43.13 | 37.47 | 36.85 | 29.92 | 23.14 |
Research & Development | 53.52 | 41.34 | 35.67 | 30.48 | 21.42 | 14.55 |
Other Operating Expenses | -1.71 | -3.06 | -0.78 | 3.23 | 1.21 | -0.43 |
Operating Expenses | 99.79 | 81.28 | 76.12 | 70.34 | 52.44 | 38.76 |
Operating Income | 199.99 | 247.55 | 209.64 | 207.33 | 124.89 | 75.36 |
Interest Expense | - | -0.03 | -0 | -0.46 | -1.97 | -3.05 |
Interest & Investment Income | 5.67 | 3.24 | 1.14 | 0.51 | 0.13 | 6.42 |
Currency Exchange Gain (Loss) | -1.18 | -1.18 | 0.11 | 0.35 | -0.02 | -0.26 |
Other Non Operating Income (Expenses) | -3.33 | -0.33 | -0.15 | -0.52 | -0.18 | -0.3 |
EBT Excluding Unusual Items | 201.14 | 249.25 | 210.74 | 207.21 | 122.85 | 78.17 |
Gain (Loss) on Sale of Investments | -0.63 | -4.58 | -2.31 | -1.85 | -1.4 | - |
Gain (Loss) on Sale of Assets | 0.1 | -0.03 | - | 0.34 | - | -0.03 |
Asset Writedown | -0.03 | - | -0.55 | -4.39 | -3.77 | -6.17 |
Pretax Income | 200.58 | 244.64 | 207.88 | 201.31 | 117.69 | 71.97 |
Income Tax Expense | 25.71 | 31.52 | 25.78 | 24.99 | 14.4 | 7.93 |
Net Income | 174.86 | 213.13 | 182.1 | 176.32 | 103.29 | 64.04 |
Net Income to Common | 174.86 | 213.13 | 182.1 | 176.32 | 103.29 | 64.04 |
Net Income Growth | -16.43% | 17.04% | 3.28% | 70.70% | 61.30% | 269.30% |
Shares Outstanding (Basic) | 143 | 100 | 100 | 100 | 96 | 95 |
Shares Outstanding (Diluted) | 143 | 100 | 100 | 100 | 96 | 95 |
Shares Change (YoY) | 72.29% | 0.07% | 0.08% | 4.17% | 0.84% | - |
EPS (Basic) | 1.22 | 2.12 | 1.82 | 1.76 | 1.07 | 0.67 |
EPS (Diluted) | 1.22 | 2.12 | 1.82 | 1.76 | 1.07 | 0.67 |
EPS Growth | -51.50% | 16.95% | 3.19% | 63.88% | 60.41% | - |
Free Cash Flow | -67.31 | 105.61 | 79.26 | 53.9 | 11.58 | 11.08 |
Free Cash Flow Per Share | -0.47 | 1.05 | 0.79 | 0.54 | 0.12 | 0.12 |
Dividend Per Share | 0.431 | 0.462 | - | - | - | - |
Gross Margin | 21.50% | 24.76% | 27.87% | 34.78% | 33.82% | 30.08% |
Operating Margin | 14.34% | 18.64% | 20.45% | 25.97% | 23.82% | 19.86% |
Profit Margin | 12.54% | 16.05% | 17.76% | 22.08% | 19.70% | 16.88% |
Free Cash Flow Margin | -4.83% | 7.95% | 7.73% | 6.75% | 2.21% | 2.92% |
EBITDA | 229.51 | 274.78 | 233.82 | 228.5 | 144.2 | 91.33 |
EBITDA Margin | 16.46% | 20.69% | 22.81% | 28.62% | 27.50% | 24.07% |
D&A For EBITDA | 29.52 | 27.23 | 24.18 | 21.17 | 19.31 | 15.97 |
EBIT | 199.99 | 247.55 | 209.64 | 207.33 | 124.89 | 75.36 |
EBIT Margin | 14.34% | 18.64% | 20.45% | 25.97% | 23.82% | 19.86% |
Effective Tax Rate | 12.82% | 12.88% | 12.40% | 12.41% | 12.23% | 11.02% |
Advertising Expenses | - | 1.01 | 1 | 0.46 | 0.21 | 0.09 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.